FDA Approves Expanded Use for Axsome Therapeutics' Auvelity in Alzheimer's Patients

Key Facts

Axsome Therapeutics has secured FDA approval to expand Auvelity's indication to Alzheimer's-related agitation, alongside reporting robust financial results. The company achieved total revenue of $191.2 million, bolstered by a significant 59% surge in AUVELITY sales. In a major pipeline update, Axsome submitted a New Drug Application (NDA) for AXS-12 to treat cataplexy in narcolepsy. Additionally, the company expanded its clinical portfolio by adding AXS-20 for the treatment of schizophrenia and Tourette syndrome. These milestones, combined with positive Phase 3 data for Auvelity, underscore the company's aggressive growth in the biotech sector. Analysts expect the combination of regulatory wins and pipeline expansion to drive long-term valuation and market share.

Version History